Genopole reveals the ten laureates of the 2024 Shaker and Gene.iO programs

Evry-Courcouronnes, France, 8 October 2024 – At its second yearly Welcome Session, Genopole, France’s leading biocluster dedicated to research in genetics and biotechnologies in healthcare and the environment, revealed the two new projects retained for its Shaker program and the eight projects retained for its Gene.iO program.

Laureates for the 15th Shaker program: two projects in health
Both of the projects retained for the 15th Shaker program concern innovative therapies. The laureates will join Genopole’s incubator (CCI Essonne) and receive personalized accompaniment during the six-month program. The Shaker’s objectives for the laureates are to scientifically validate their research and thereafter help them create their own start-ups.

The 15th-edition Shaker projects:

• 🏆  SWABIOT is forwarding an innovative medical device for self-diagnosing common vaginal infections. The device calls upon multiplex immunochromatography technology and the project’s goal is to reduce the delay to treatment, currently 64 days in France.
• 🏆  Ormusol is developing a natural-ingredients-based mouthwash aimed at protecting, sanitizing and healing mouth mucosal membranes damaged by cancer therapies.

Laureates for the fourth Gene.iO program: eight projects retained

Of the eight Gene.iO 2024 laureates, six are Shaker graduates, four are working in the field of health and four in the bioeconomy. They will join the fourth edition of the acceleration program scheduled to begin on 4 November 2024. Their accompaniment will include a €20,000 repayable advance as a first decisive funding source to enable upscaling, the development of a new product or service, and arrival on the market.

The 2024 Gene.iO projects:

• 🏆 Papilio.Bio (Shaker graduate) is developing a rapid self-testing kit to detect human papillomavirus (HPV) infection in women or men and an HPV information app to make prevention accessible, reach unscreened populations and eliminate HPV-associated cancers, particularly cervical cancer.
• 🏆 Synanthra (Shaker graduate) is producing ammonia through a microorganism-driven biosynthesis process that greatly reduces CO₂ emissions.
• 🏆 MicroXpace (Shaker graduate) proposes innovative probiotic approaches to controlling parasitic diseases in aquaculture, poultry and pets.
• 🏆 ORINOVA is developing an oncological nanotechnology that delivers a chemotherapeutic agent and gold nanoparticles to increase radiation therapy efficacy and enable imaging-guided bitherapies. This patented and innovative nanomedicine approach shows great potential for the treatment of solid tumors currently lacking satisfactory therapeutic solutions, such as glioblastomas.
• 🏆 PhairiLab is a specialist in R&D for polymolecular drugs originating from the biodiversity of Columbia.
• 🏆 So Sweet (Shaker graduate) produces next-generation sweeteners from plant proteins extracted through an innovative process. The company seeks to respond to the food industry’s need to reduce sugar use while improving the taste of its products.
• 🏆 VRAI-Heart (Shaker graduate) is developing an unprecedented virtual-reality and artificial-intelligence based system to enable an extremely precise and patient-specific model of the heart that can be explored intuitively and in real time for preoperative visualization and intraoperative navigation.
• 🏆 Blue2 (Shaker graduate) harnesses the potential of microalgae to enable the conversion of industrial CO₂ into biosourced energy, compounds of interest or chemical products.

• About Genopole

  Genopole is a French biocluster dedicated to research in genetics and biotechnologies in healthcare and the environment. It unites 66 biotech companies, 17 research laboratories and 24 technological platforms, as well as a range of tertiary-level training programs with the University of Évry-Paris Saclay.
  Genopole’s objectives are to support biotech companies and the transfer of technologies to the industrial sector, favor the development of life sciences research, and promote advanced training programs for those domains.
  Under the presidency of Stéphane Beaudet, vice-president of the Île-de-France Administrative Region and mayor of Évry-Courcouronnes, and the direction of Gilles Trystram, Genopole is funded primarily by the French State, the Île-de-France Region, the Grand Paris Sud Urban Area and the AFM-Téléthon.

  *figures on December 31, 2023

Article posted on 9 October 2024

Share